Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer

Int J Urol. 2005 Nov;12(11):1012-3. doi: 10.1111/j.1442-2042.2005.01196.x.

Abstract

Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Bone Marrow Neoplasms / drug therapy
  • Bone Marrow Neoplasms / secondary
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Hematuria / etiology
  • Humans
  • Hydronephrosis / etiology
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Renal Dialysis
  • Renal Insufficiency / etiology
  • Renal Insufficiency / therapy
  • Tumor Lysis Syndrome / etiology*

Substances

  • Antineoplastic Agents, Phytogenic
  • Prostate-Specific Antigen
  • Paclitaxel